Pfizer, Lilly, AbbVie engage in JAKi battle in KOR
By Nho, Byung Chul | translator Kim, Jung-Ju
23.07.01 06:00:28
가나다라
0
Q1 2023 sales of Xeljanz, Olumiant and Rinvoq: KRW 3.3 billion, 3.7 billion, and 3.5 billion
Market size of KRW 40 billion… 'Blue Ocean' with annual growth of KRW 10 billion
Rinvoq and Olumiant effective in atopic dermatitis and alopecia areata... Cibinqo joins competition
Pfizer's Xeljanz and Lilly's Olumiant are engaged in an intense competition for sales in the JAK inhibitor market.
According to the distribution data of pharmaceuticals, Xeljanz (including Xeljanz XR) recorded sales of KRW 15.5 billion won last year, while Olumiant recorded KRW 15.4 billion.
Although Xeljanz maintained a slight lead, Olumiant has shown a faster infiltration rate in terms of growth.
Olumiant's sales in 2019, 2020, 2021, and 2022 were KRW 2.2 billion, 9 billion, 12.6 billion, and 15.4 billion, respectively, representing a 600% increase over four years.
During the same period, Xeljanz recorded sales of KRW 14.6 billion, 16.2 billion, 15
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)